logo

Durect Corp. (DRRX)



Trade DRRX now with
  Date
  Headline
12/22/2021 7:33:00 AM DURECT, Innocoll Announce $136 Mln U.S. Licensing Agreement For POSIMIR
11/10/2021 9:04:07 AM DURECT Doses First Ex-U.S. Patient In Phase 2b Study Of Larsucosterol In Severe Alcohol-Associated Hepatitis
6/23/2021 9:10:17 AM DURECT Presents Addl Clinical Data From DUR-928 Phase 1b Trial In NASH And Phase 1 Trial In Hepatic Impairment
6/9/2021 9:13:54 AM DURECT To Present Additional Clinical Data From DUR-928 Studies In NASH And In Hepatic Impairment
3/4/2021 4:06:58 PM DURECT Corp. Q4 EPS $0.02 Vs. Loss $0.02 Year Ago
2/4/2021 9:20:01 AM DURECT Corp. Pricing Of $42.5 Mln Public Offering Of Common Stock
2/2/2021 8:14:05 AM DURECT Says FDA Has Approved POSIMIR For Infiltration Use
1/25/2021 8:54:23 AM DURECT Says First Patient Dosed In Phase 2b AHFIRM Study Of DUR-928 In Severe Alcohol-Associated Hepatitis
1/4/2021 8:57:29 AM DURECT Announces Closing Of LACTEL Absorbable Polymer Product Line Sale To Evonik And Receipt Of $15 Mln
12/16/2020 8:32:44 AM DURECT Says FDA Granted Fast Track Designation To DUR-928 For Treatment Of Alcoholic Hepatitis
11/13/2020 9:08:42 AM DURECT Announces Addl Safety Data And Efficacy Signals From Phase 1b Clinical Trial Of DUR-928 In NASH Patients
9/23/2020 8:36:00 AM DURECT: First Patient Dosed In Phase 2 Study Of DUR-928 In COVID-19 Patients With Acute Liver Or Kidney Injury
9/22/2020 8:34:41 AM DURECT Announces Study Design For Phase 2b AHFIRM Clinical Trial Of DUR-928 In Severe AH Patients
8/27/2020 8:36:15 AM DURECT Announces Presentation Of Phase 2a Pharmacokinetic Data Of DUR-928 In Alcoholic Hepatitis
7/1/2020 8:46:52 AM DURECT Begins Recruiting Patients For Phase 2 Study On DUR-928 In COVID-19 Patients With Acute Liver Or Kidney Injury